减少大脑Aβ负担可以改善APP/PS1小鼠的高脂肪饮食引起的脂肪肝疾病
Huey-Jen Tsay1, Yu-Ling Gan2, Yu-Han Su2
1Institute of Neuroscience, School of Life Science, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
概括
抗粉样蛋白免疫疗法 (NP106) 减少了阿尔茨海默病的病理学,并改善了高脂肪饮食中的小鼠的认知能力. 令人惊的是,它还逆转了脂肪肝疾病,这表明阿尔茨海默氏症治疗的系统方法.
科学领域:
- 神经科学是一个神经科学.
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
背景情况:
- 高脂肪饮食 (HFD) 诱导的脂肪肝疾病加剧了阿尔茨海默病 (AD) 的病理.
- 抗阿茲海默症免疫治療對HFD引起的脂肪肝的影響尚不清楚.
- 在代谢功能障碍的背景下,研究针对AD的Aβ清除疗法至关重要.
研究的目的:
- 评估抗-Aβ抗体NP106在AD小鼠模型中与长期HFD暴露的治疗潜力.
- 为了确定NP106治疗是否可以减轻AD类病理和HFD诱导的脂肪肝疾病.
- 探索Aβ向免疫疗法的全身效应.
主要方法:
- 在44周的时间里,APP/PS1小鼠被食了一种HFD.
- 在最后的18周内进行了NP106治疗.
- 评估了与脂质代谢相关的Aβ负担,认知功能,微质活动,肝病理和基因表达.
主要成果:
- 在HFD养小鼠中,NP106治疗显著降低了Aβ负担,神经炎症和认知缺陷.
- 增强了Aβ的微细胞化,减少了脂质积累.
- NP106改善了HFD引起的高血糖症,脂肪肝,肝纤维化和肝脂含量.
- 大脑Aβ负担和认知缺陷与脂肪肝严重程度和葡萄糖水平正相关.
结论:
- 抗Aβ免疫疗法 (NP106) 在小鼠中有效缓解AD类疾病和脂肪肝疾病.
- 治疗阿尔茨海默病的治疗策略应该考虑一种系统的方法,解决中心病理和外周代谢条件之间的相互作用.
- 准Aβ可能为神经和代谢疾病提供双重好处.
更多相关视频
相关概念视频
01:26Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21